Chicago Partners Investment Group LLC cut its holdings in shares of Invesco Pharmaceuticals ETF (NYSEARCA:PJP – Free Report) by 18.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,866 shares of the company’s stock after selling 632 shares during the quarter. Chicago Partners Investment Group LLC owned 0.08% of Invesco Pharmaceuticals ETF worth $219,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. Principal Securities Inc. acquired a new stake in Invesco Pharmaceuticals ETF during the 4th quarter worth approximately $31,000. Kraft Davis & Associates LLC acquired a new stake in Invesco Pharmaceuticals ETF during the 4th quarter worth approximately $277,000. Modera Wealth Management LLC acquired a new stake in Invesco Pharmaceuticals ETF during the 3rd quarter worth approximately $538,000. Commonwealth Retirement Investments LLC acquired a new stake in shares of Invesco Pharmaceuticals ETF in the 4th quarter valued at $1,557,000. Finally, Joseph Group Capital Management acquired a new stake in shares of Invesco Pharmaceuticals ETF in the 4th quarter valued at $2,121,000.
Invesco Pharmaceuticals ETF Trading Down 0.1 %
Shares of PJP opened at $81.16 on Wednesday. Invesco Pharmaceuticals ETF has a twelve month low of $67.75 and a twelve month high of $83.05. The firm’s fifty day simple moving average is $79.19 and its 200-day simple moving average is $77.63. The firm has a market capitalization of $275.13 million, a price-to-earnings ratio of 21.48 and a beta of 0.61.
About Invesco Pharmaceuticals ETF
PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
Featured Stories
- Five stocks we like better than Invesco Pharmaceuticals ETF
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Occidental Stock: Buffett’s 9-Day Buying Spree Lifts Stake to 29%
- What to Know About Investing in Penny Stocks
- 3M Stock: Invest Now for Unmatched Quality and Growth Potential
- What is MarketRank™? How to Use it
- Super Micro AI Stock: Should You Invest After a 275% Increase?
Receive News & Ratings for Invesco Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
